Alloantibodies that are non ABO Alloimmunization to protein antigens happens only after exposure, in contrast to ABO isohaemagglutinins, which are present naturally, even in the absence of prior exposure. It is recogn...Alloantibodies that are non ABO Alloimmunization to protein antigens happens only after exposure, in contrast to ABO isohaemagglutinins, which are present naturally, even in the absence of prior exposure. It is recognized that while non-ABO RBC antibodies are less common than ABO antibodies, they generate essentially the same issues that lead to unfavorable clinical results. If non-ABO alloantibodies are identified early on, these issues related complications may be avoided This call for an in-depth understanding of the recipient and donor’s ABO-Rh grouping, antibody screening, and the phenotype of certain antigens. Equally important, the temporal association time between transplantation and hemolysis can help identify the underlying mechanism of hemolysis and direct appropriate management. Therefore, for that, it is crucial to identify the etiology of post-HSCT anemia for prevention and therapy, in addition to a thorough grasp of the mechanism of anemia in non-ABO-incompatible HSCT and the temporal link between HSCT and anemia. Finding the cause of post-HSCT anemia is essential for prevention and therapy, in addition to a thorough grasp of the mechanism of anemia in non-ABO-incompatible HSCT and the temporal link between HSCT and anemia. Therefore, for that, it is crucial to identify the etiology of post-HSCT anemia. In this case report review, we would like to highlight the vital role of transfusion medicine services and stem cell clinical teams in paying particular attention to the clinical significance of non-ABO alloantibodies involved to avoid causing overt hemolysis of incompatible donor RBCs or delayed erythropoiesis. Considering the fact that some of the Haematopoietic stem cell transplant centers do not give an attention to the other non-ABO RBC antigens.展开更多
目的探讨意外抗体致非ABO-胎儿/新生儿溶血病(non-ABO hemolytic disease of the fetus and newborn,non-ABO HDFN)血型血清学分析及临床干预结果比较,为临床准确诊治提供参考。方法回顾性分析2015年1月~2020年8月期间新生儿科送检,陕...目的探讨意外抗体致非ABO-胎儿/新生儿溶血病(non-ABO hemolytic disease of the fetus and newborn,non-ABO HDFN)血型血清学分析及临床干预结果比较,为临床准确诊治提供参考。方法回顾性分析2015年1月~2020年8月期间新生儿科送检,陕西省血液中心血型参比室进行检测并最终证实的20例非ABO-HDFN病例,鉴定20例母亲血清及患儿红细胞放散液中的意外抗体及效价;并按照临床干预方式的不同,将患儿分为光疗组、光疗后换血组和光疗后输血组,采用Kruskal-Wallis检验比较三组之间平均住院天数的差异。结果20例非ABO-HDFN涉及到4个血型系统的9种意外抗体。三组之间平均住院天数比较,输血组平均住院天数最高(15.8±6.94天),换血组次之(11.25±2.86天),光疗组最短(8.5±1.89天),三组之间平均住院天数差异有统计学意义(χ^(2)=8.046,P=0.018)。结论血型血清学检测分析是提高由意外抗体致非ABO-HDFN重要检测手段,临床应根据检出抗体的特性及患儿的病情轻重来评估其风险,及时对患儿采取必要的干预手段,对改善患儿预后具有参考价值。展开更多
文摘Alloantibodies that are non ABO Alloimmunization to protein antigens happens only after exposure, in contrast to ABO isohaemagglutinins, which are present naturally, even in the absence of prior exposure. It is recognized that while non-ABO RBC antibodies are less common than ABO antibodies, they generate essentially the same issues that lead to unfavorable clinical results. If non-ABO alloantibodies are identified early on, these issues related complications may be avoided This call for an in-depth understanding of the recipient and donor’s ABO-Rh grouping, antibody screening, and the phenotype of certain antigens. Equally important, the temporal association time between transplantation and hemolysis can help identify the underlying mechanism of hemolysis and direct appropriate management. Therefore, for that, it is crucial to identify the etiology of post-HSCT anemia for prevention and therapy, in addition to a thorough grasp of the mechanism of anemia in non-ABO-incompatible HSCT and the temporal link between HSCT and anemia. Finding the cause of post-HSCT anemia is essential for prevention and therapy, in addition to a thorough grasp of the mechanism of anemia in non-ABO-incompatible HSCT and the temporal link between HSCT and anemia. Therefore, for that, it is crucial to identify the etiology of post-HSCT anemia. In this case report review, we would like to highlight the vital role of transfusion medicine services and stem cell clinical teams in paying particular attention to the clinical significance of non-ABO alloantibodies involved to avoid causing overt hemolysis of incompatible donor RBCs or delayed erythropoiesis. Considering the fact that some of the Haematopoietic stem cell transplant centers do not give an attention to the other non-ABO RBC antigens.
文摘目的探讨意外抗体致非ABO-胎儿/新生儿溶血病(non-ABO hemolytic disease of the fetus and newborn,non-ABO HDFN)血型血清学分析及临床干预结果比较,为临床准确诊治提供参考。方法回顾性分析2015年1月~2020年8月期间新生儿科送检,陕西省血液中心血型参比室进行检测并最终证实的20例非ABO-HDFN病例,鉴定20例母亲血清及患儿红细胞放散液中的意外抗体及效价;并按照临床干预方式的不同,将患儿分为光疗组、光疗后换血组和光疗后输血组,采用Kruskal-Wallis检验比较三组之间平均住院天数的差异。结果20例非ABO-HDFN涉及到4个血型系统的9种意外抗体。三组之间平均住院天数比较,输血组平均住院天数最高(15.8±6.94天),换血组次之(11.25±2.86天),光疗组最短(8.5±1.89天),三组之间平均住院天数差异有统计学意义(χ^(2)=8.046,P=0.018)。结论血型血清学检测分析是提高由意外抗体致非ABO-HDFN重要检测手段,临床应根据检出抗体的特性及患儿的病情轻重来评估其风险,及时对患儿采取必要的干预手段,对改善患儿预后具有参考价值。
